Pharma IQ Members


Discover results-proven tools and methodologies for your clinical development. Learn how to improve your trial design, data collection and clinical supply. In addition, get key information on how to improve your patient recruitment and retention. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in clinical development to exchange ideas on best practice and share case studies on innovation within the area.

Contributor: Pharma IQ News
Posted: 18/10/2016
Pharma IQ News
Following a quarter that featured reports stating that Novartis had dramatically redistributed its cell and gene therapy unit 1 and saw the public focus turn once again to drug price hikes, Pharma IQ brings you the pharma, biotech and life sciences news highlights for Q3 of 2016. Full Article »
Posted: 21/10/2013
Experiences with IRT- An Interview with CTS manager Michael Pompey
Ahead of the Clinical Trial Supply Europe event, Pharma IQ presents interviews filmed live at last year's CTS event. In this interview Michael Pompey talks about the daily challenges he faces as a clinical trial supply manager at Sandoz and he discusses his experience with IRT. Full Video »
Contributor: Gerald Clarke
Posted: 01/10/2013
For Dr Hella Kohlhof, the study of epigenetics was not love at first sight, however the potential it posesses eventually won her over. Now Dr Kohlhof is Manager of Translational Pharmacology at 4SC AG and is applying epigenetic knowledge in a phase 1 first-in-man trial. She talks to us about what role epigentics plays in cancer and how new Full Podcast »
Contributor: Regina Au
Posted: 25/10/2016
Regina Au
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells, leading to major side effects such as loss of hair, nausea and vomiting, and risk of infection. Survival was sometimes better, but not much better, depending on the type of cancer and the patient's own genetic and physiological make-up. The big advantage of IO therapies is that they can target specific receptors on the cancer cells and destroy them while leaving the healthy cells alone. This will also help reduce some of the traditional side effects when healthy cells are destroyed. Full Column »
Contributor: Miss Chanice Henry
Posted: 04/10/2016
Miss Chanice Henry
Pharma IQ speaks to Dr Samantha Carmichael, Lead Pharmacist Clinical Trials of NHS Greater Glasgow & Clyde and Mandy Wan, Lead Paediatric Research Pharmacist, Evelina London Children’s Hospital in regards to the growing culture of site centricity in today’s clinical trials. Full Whitepaper »